

1 **Analysis of anti-Omicron neutralizing antibody titers in different vaccinated and unvaccinated**  
2 **convalescent plasma sources.**

3

4 David J Sullivan<sup>1</sup> Massimo Franchini<sup>2</sup>, Michael J. Joyner<sup>3</sup>, Arturo Casadevall<sup>1</sup>, Daniele Focosi<sup>4,#</sup>,

5

6 <sup>1</sup>Johns Hopkins Bloomberg School of Public Health and School of Medicine, Baltimore, MD 21218, USA;  
7 [dsullivan7@jhmi.edu](mailto:dsullivan7@jhmi.edu), [acasade1@jhu.edu](mailto:acasade1@jhu.edu),

8 <sup>2</sup>Division of Transfusion Medicine, Carlo Poma Hospital, 46100 Mantua, Italy; [massimo.franchini@asst-](mailto:massimo.franchini@asst-mantova.it)  
9 [mantova.it](mailto:mantova.it)

10 <sup>3</sup>Department of Anesthesiology & Perioperative Medicine, Mayo Clinic, Rochester, MN 55902, USA  
11 [joyner.michael@mayo.edu](mailto:joyner.michael@mayo.edu) ;

12 <sup>4</sup>North-Western Tuscany Blood Bank, Pisa University Hospital, 56124 Pisa, Italy.

13

14 <sup>#</sup>corresponding author: via Paradisa 2, 56124 Pisa, Italy. E-mail: [daniele.focosi@gmail.com](mailto:daniele.focosi@gmail.com) .

15 **Keywords:** COVID19; Omicron; convalescent plasma; vaccine; neutralizing antibodies.

16 **Word count:** abstract 220; body 2979.

17 **Acknowledgements:** none.

18 **Funding Information:** The analysis was supported by the U.S. Department of Defense's Joint Program  
19 Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in  
20 collaboration with the Defense Health Agency (DHA) (contract number: W911QY2090012) (D.S), with  
21 additional support from Bloomberg Philanthropies, State of Maryland, the National Institutes of Health  
22 (NIH) National Institute of Allergy and Infectious Diseases (NIAID) 3R01AI152078-01S1) (A.C).

23 **Author contributions:** D.F. and M.J.J. conceived the manuscript; D.F., D.J.S. and M.F. analyzed the  
24 literature, curated tables and wrote manuscripts; M.F. provided Figure 1; D.J.S. provided Figures 2 -5.A.C.  
25 and M.J.J. revised the manuscript.

26 **Data availability statement:** The datasets generated during and/or analysed during the current study are  
27 available from the corresponding author on reasonable request

## 28 Abstract

29 The latest SARS-CoV-2 variant of concern Omicron, with its immune escape from therapeutic anti-Spike  
30 monoclonal antibodies and WA-1 vaccine-elicited sera, demonstrates the continued relevance of COVID-  
31 19 convalescent plasma (CCP) therapies. Lessons learnt from previous usage of CCP suggests focusing on  
32 early outpatients and immunocompromised recipients, with high neutralizing antibody (nAb) titer units.  
33 In this analysis we systematically reviewed Omicron-neutralizing plasma activity data, and found that  
34 approximately 47% (424/902) of CCP from unvaccinated pre-Omicron donors neutralizes Omicron BA.1  
35 with a very low geometric mean of geometric mean titers for 50% neutralization  $GM(GMT_{50})$  of about 13,  
36 representing a more than 20-fold reduction from WA-1 neutralization. Two doses of mRNA vaccines in  
37 nonconvalescent subjects had a similar 50% percent neutralization with Omicron BA.1 neutralization  
38  $GM(GMT_{50})$  of about 27. However, plasma from vaccinees recovered from either previous pre-Omicron  
39 variants of concern infection, Omicron BA.1 infection, or third-dose uninfected vaccinees was nearly  
40 100% neutralizing against Omicron BA.1, BA.2 and BA.4/5 with  $GM(GMT_{50})$  all over 189, 10 times higher  
41 than pre-Omicron CCP. Fully vaccinated and post-BA.1 plasma (Vax-CCP) had  $GM(GMT_{50})$  over 450 for  
42 BA.4/5 and over 1500 for BA.1 and BA.2. These findings have implications for both CCP stocks collected in  
43 prior pandemic periods and plans to restart CCP collections. Thus, Vax-CCP provides an effective tool to  
44 combat ongoing variants that defeat therapeutic monoclonal antibodies.

## 45 Introduction

46 The SARS-CoV-2 Omicron variant of concern (VOC) (originally named VUI-21NOV-01 by Public Health  
47 England and belonging to GISAID clade GRA(B.1.1.529+BA.\*) was first reported on November 8, 2021 in  
48 South Africa, and shortly thereafter was also detected all around the world. Omicron mutations impact  
49 27% of T cell epitopes<sup>1</sup> and 31% of B cell epitopes of the Spike protein, while percentages for other VOC  
50 were much lower<sup>2</sup>. The Omicron variant has further evolved to several sublineages which are named by  
51 PANGO phylogeny using the BA alias: the BA.1 wave of Winter 2021-2022 has been suddenly replaced by  
52 BA.2 and BA.2.12.1 in Spring 2022, and by the BA.4 and BA.5 waves in Summer 2022.

53  
54 The VOC Omicron is reducing the efficacy of all vaccines approved to date (unless 3 doses are delivered)  
55 and is initiating an unexpected boost in COVID19 convalescent plasma (CCP) usage, with Omicron being  
56 treated as a shifted novel virus instead of a SARS-CoV-2 variant drift. Two years into the pandemics, we  
57 are back to the starting line for some therapeutic classes. Specifically, Omicron escapes viral  
58 neutralization by most monoclonal antibodies (mAbs) authorized to date with the lone exception of  
59 bebtelovimab<sup>3</sup>. Despite the development of promising oral small-molecule antivirals (molnupiravir and  
60 nirmatrelvir), the logistical and economical hurdles for deploying these drugs worldwide has prevented  
61 their immediate and widespread availability, and concerns remain regarding both molnupiravir (both  
62 safety<sup>4</sup> and efficacy<sup>5</sup>) and nirmatrelvir (efficacy), especially in immunocompromised subjects. CCP was  
63 used as a frontline treatment from the very beginning of the pandemic. Efficacy outcomes have been  
64 mixed to date, with most failures explained by low dose, late usage, or both, but efficacy of high-titer CCP  
65 has been definitively proven in outpatients with mild disease stages<sup>6,7</sup>. Neutralizing antibody (nAb)  
66 efficacy against VOC remains a prerequisite to support CCP usage, which can now be collected from  
67 vaccinated convalescents, including donors recovered from breakthrough infections (so-called “hybrid  
68 plasma” or “Vax-CCP”)<sup>8</sup>: pre-Omicron evidence suggest that those nAbs have higher titers and are more  
69 effective against VOCs than those from unvaccinated convalescents<sup>9,10</sup>. From a regulatory viewpoint, to  
70 date, plasma from vaccinees that have never been convalescent does not fall within the FDA emergency  
71 use authorization

72 There are tens of different vaccine schedules theoretically possible according to EMA and FDA approvals,  
73 including a number of homologous or heterologous boosts, but the most commonly delivered schedules  
74 in the western hemisphere have been: 1) BNT162b2 or mRNA-1273 for 2 doses eventually followed by a  
75 homologous boost; 2) ChAdOx1 for 2 doses eventually followed by a BNT162b2 boost; and 3)  
76 Ad26.COV2.S for 1 dose eventually followed by a BNT162b2 boost<sup>11</sup>. Many more inactivated vaccines  
77 have been in use in low-and-middle income countries (LMIC), which are target regions for CCP therapy:  
78 this is feasible given the lower number of patients at risk for disease progression there (lower incidences  
79 of obesity, diabetes, and hypertension, and lower median age) and the already widespread occurrence of  
80 collection and transfusion facilities. Most blood donors there have already received the vaccine schedule  
81 before, after or without having been infected, with a nAb titer generally declining over months<sup>12</sup>. Hence  
82 identifying the settings where the nAb titer is highest will definitively increase the efficacy of CCP  
83 collections. Variations in nAb titers against a given SARS-CoV-2 strain are usually reported as fold-changes  
84 in geometric mean titer of antibodies neutralizing 50% of cytopathic effect (GMT<sub>50</sub>) compared to wild-  
85 type strains: nevertheless, fold-changes for groups that include non-responders can lead to highly  
86 artificial results and possibly over-interpretation. Rigorous studies have hence reported the percentage of

87 responders as primary outcome and provided fold-changes of GMT<sub>50</sub> where calculation is reasonable  
88 (100% responders in both arms)<sup>13</sup>.

89 To date the most rigorous data repository for SARS-CoV-2 sensitivity to antivirals is the Stanford  
90 University Coronavirus Antiviral & Resistance Database, but as of July 24, 2022 the tables there  
91 summarizing “Convalescent plasma” and “Vaccinee plasma” (<https://covdb.stanford.edu/search-drdb>) do  
92 not dissect the different heterologous or homologous vaccination schemes, the simultaneous occurrence  
93 of vaccination and convalescence, or the time from infection/vaccine to neutralization assay.  
94 Consequently, a more in-depth analysis is needed to better stratify CCP types.

95

## 96 Methods

97 On August 11, 2022, we searched PubMed, medRxiv and bioRxiv for research investigating the efficacy of  
98 CCP (either from vaccinated or unvaccinated donors) against SARS-CoV-2 VOC Omicron (pre)published  
99 after December 1, 2019, using English language as the only restriction. In PubMed we used the search  
100 query (“convalescent plasma” or “convalescent serum”) AND (“neutralization” or “neutralizing”) AND  
101 “SARS-CoV-2”, while in bioRxiv and medRxiv we searched for abstract or title containing “convalescent,  
102 SARS-CoV-2, neutralization” (match all words). When a preprint was published, the latter was used for  
103 analysis. We also screened the reference lists of reviewed articles for additional studies not captured in  
104 our initial literature search. Articles underwent evaluation for inclusion by two assessors (D.F. and D.J.S.)  
105 and disagreements were resolved by a third senior assessor (A.C.). We excluded review articles, meta-  
106 analyses, studies reporting antibody levels by serological assays other than neutralization, as well as  
107 studies exclusively analyzing nAbs in vaccine-elicited plasma/serum from non-convalescent subjects. In  
108 unvaccinated subjects, convalescence was annotated according to infecting sublineage (pre-VOC Alpha,  
109 VOC Alpha, VOC Beta, VOC Delta, or VOC Omicron BA.1 sublineages). Given the heterologous immunity  
110 that develops after vaccination in convalescents, the infecting lineage was not annotated in vaccine  
111 recipients. In vaccinees, strata were created for 2 homologous doses, 3 homologous doses, or post-  
112 COVID-19 and post-vaccination (Vax-CCP). The type of viral assay (live or pseudovirus), time interval to  
113 blood sample, geometric mean, minimum and maximum neutralizing 50% dilutional titer for WA-1 (pre-  
114 Alpha wild-type) and Omicron sublineages BA.1, BA.2 and BA.4/5, and number out of total that  
115 neutralized Omicron was abstracted from study text, graphs and tables.

116 Statistical significance between log<sub>10</sub> transformed geometric study means was investigated using Tukey’s  
117 test.

118

## 119 Results

120 Our literature search identified 31 studies dealing with the original Omicron lineage (BA.1), that were  
121 then manually mined for relevant details: the PRISMA flowchart for study selection is provided in Figure  
122 1. Given the urgency to assess efficacy against the upcoming VOC Omicron, many studies (with a few  
123 exceptions<sup>14, 15, 16, 17</sup>) relied on Omicron BA.1 pseudovirus neutralization assays, which, as opposed to live  
124 authentic virus neutralization assays, are scalable, do not require BSL-3 facilities, and provide results in

125 less than 1 week. Plasma dilutions were expressed in the studies as GMT<sub>50</sub> of nAb, and fold-reduction in  
126 GMT<sub>50</sub> compared to wild-type SARS-CoV-2 (e.g., WA-1) was the most common way of reporting changes,  
127 which reduces variability due to differences in the neutralization assays used. In comparing the large  
128 number of diverse studies with more than 100-fold plasma dilutional titers, we took the geometric mean  
129 of the individual study GMT<sub>50</sub>, deriving a geomean of GMT<sub>50</sub> (GM(GMT<sub>50</sub>)).

130 Figure 2 and Table 1 summarize that neutralizing activity to WA-1 from CCP collected from subjects  
131 infected with pre-Alpha SARS-CoV-2 (Supplementary Table 1), Alpha VOC (Supplementary Table 2), Beta  
132 VOC (Supplementary Table 3), Delta VOC (Supplementary Table 4) or plasma from nonconvalescent  
133 subjects vaccinated with 2 mRNA vaccine doses (Supplementary Tables 5 and 6). The same plasma types  
134 computed a geometric mean of multiple GMT<sub>50</sub> from many studies with about a 20-fold reduction against  
135 BA.1 geomeans compared to wild-type SARS-CoV-2 geomeans. CCP from uninfected vaccinees receiving a  
136 third vaccine dose registered a geomean of the GMT<sub>(50)</sub> of 2,588 (or 10- fold higher nAb geomean of the  
137 GMT<sub>50</sub>) to pre-alpha CCP viral assays. In this group the nAb geomean of the GMT<sub>50</sub> fold-reduction against  
138 BA.1 was 9, but importantly the geomean of the GMT<sub>(50)</sub> was close to 300, similar to WA-1 inhibition by  
139 WA-1 CCP. The approximately 21-fold reduction in geomean of the GMT<sub>(50)</sub> from wild-type to BA.1 was  
140 reversed by the 10-15-fold increase in nAb geomean of the GMT<sub>(50)</sub> from either boosted (third-dose)  
141 vaccination or Vax-CCP.

142 In addition to the nAb GMT<sub>50</sub> levels showing potency, the percentage of individuals within a study cohort  
143 positive for any level of BA.1 neutralization shows the likelihood of a possible donation having anti-BA.1  
144 activity. All studies but one tested a limited number of 20 to 40 individuals. The pre-Alpha CCP showed  
145 that most (18 of 27 studies) had fewer than 50% of individuals tested within a study with measurable  
146 BA.1 neutralizing activity: only 2 out of 27 studies indicated that 100% of individuals tested showed BA.1  
147 neutralization (Figure 3). Likewise, most of the studies investigating Alpha and Beta CCP showed similar  
148 percent with nAb. Delta CCP had 6 of 7 studies with more than 50% BA.1 neutralization. The plasma from  
149 studies of the 2-dose mRNA vaccines indicated a more uniform distributive increase in percent of  
150 individual patients with measurable Omicron BA.1 nAb's. The stark contrast is pre-Omicron Vax-CCP,  
151 where 14 of 17 studies had 100% of individuals tested with anti-BA.1 nAb. The 3-dose vaccinee studies  
152 similarly had 12 of 17 studies with 100% measurable nAb.

153 Five studies directly compared anti-WA-1 to BA.1 nAb titers in nonvaccinated pre-Alpha, Alpha, Beta, and  
154 Delta CCP, and vaccinated plasma with the same nAb assay (Figure 4). nAb GMT<sub>50</sub> against WA-1 was  
155 higher for Alpha CCP but lower for Beta CCP. nAb geomean of the GMT<sub>(50)</sub> against BA.1 was actually  
156 highest for delta CCP with geomean levels of 6, 6, 10 for pre-Alpha, Alpha and Delta (Figure 4, panel A). In  
157 these 5 studies, nAb geomean of the GMT<sub>(50)</sub> rose from 2-dose vaccinations to Vax-CCP to the 3-dose  
158 boosted vaccination. Importantly, for nAb, geomean of the GMT<sub>(50)</sub> against BA.1 were 14 to 103 to 195,  
159 respectively (Figure 4, panel B).

160 Another set of 9 matched vaccination studies inclusive of plasma collected after 2- and 3-dose schedules,  
161 as well as Vax-CCP, depicted a 20-fold rise in the geomean of the GMT<sub>(50)</sub> of anti-BA.1 nAb from the 2-  
162 dose vaccine to post COVID-19 vaccinees, and a 21-fold increase after the third vaccine dose. The pattern  
163 was similar for nAb geomean of the GMT<sub>(50)</sub> against WA-1 (Figure 4, panel C).

164 The AZD1222, 3-dose mRNA-1273 and Ad26.CO2 vaccines were understudied, with 3 or less  
165 independent studies at different time points, reported in Table 10. The GMT<sub>50</sub> nAb to BA.1 after 3-

166 mRNA-1273 doses ranged 60 to 2000, with a 5-to-15-fold reduction compared with WA-1. GMT<sub>50</sub> of anti-  
167 BA.1 nAbs after AZD1222 vaccine was modest (~10 to 20), as with Ad26.COVID vaccine (~20 to 40). Two  
168 studies reported on post-COVID-19/post-mRNA-1273 with nAb GMT<sub>50</sub> against BA.1 of 38 and 272. Studies  
169 with 100% of individual patient samples neutralizing BA.1 included 2 3-dose mRNA-1273 studies, one  
170 AZD1222 study, and one post-COVID-19/post-mRNA-1273 study.

171 Few data exist for comparisons among different vaccine boosts. For CoronaVac® (SinoVac), three doses  
172 led to 5.1 fold reduction in anti-BA.1 nAb GMT<sub>50</sub> compared to wild-type<sup>18</sup>, while for Sputnik V nAb titer  
173 moved from a 12-fold reduction at 6-12 months up to a 7-fold reduction at 2-3 months after a boost with  
174 Sputnik Light<sup>19, 20</sup>. These *in vitro* findings have been largely confirmed *in vivo*, where prior heterologous  
175 SARS-CoV-2 infection, with and without mRNA vaccination, protects against BA.1 re-infection<sup>21</sup>.

176 Eleven studies analyzed the efficacy of CCP and Vax-CCP against Omicron sublineages other than BA.1,  
177 i.e. BA.2 and BA.4/5 (summarized in Table 2, Figure 5 and supplement Table 10, 11 and 12). Pre-Omicron  
178 (mainly Delta) CCP neutralized less than 40% of BA.1, BA.2 and BA.4/5. Unvaccinated individuals in 3  
179 studies only with BA.1 primary infections poorly neutralized WA-1, with about 75% neutralizations of  
180 BA.1, BA.2 and BA.4/5. The 3 vaccine doses of BNT162b2 in 8 studies had a 7-, 6- and 16-fold reduction  
181 from WA-1 GM(GMT<sub>50</sub>) of 3,247 with percent of neutralizations all over 95%. Individuals from 11  
182 populations with a BA.1 VaxCCP had a 2-, 2- and 8-fold reduction for WA-1 GM(GMT<sub>50</sub>) of 3578, with 99%  
183 Omicron neutralizations. Importantly, GM(GMT<sub>50</sub>) of BA.1 Vax-CCP was more than 1.5 times higher than  
184 that of pre-alpha CCP for WA-1. Omicron BA.1, BA.2 and BA.4/5 percent neutralization was over 99% for  
185 each. In conclusion, BA.1-Vax- CCP was both high-titer and high neutralization percent.

186 These studies largely confirm that Omicron CCP *per se* is poorly effective against the cognate or other  
187 Omicron sublineages<sup>22</sup> (with the lone exception of cross-reactions among lineages sharing L452  
188 mutations<sup>23</sup> and broad-spectrum nAbs elicited by BA.5<sup>24</sup>). By contrast, both the homologous and the  
189 heterologous efficacy of Omicron Vax-CCP is universally preserved<sup>15, 25</sup>. Despite evidence that  
190 concentrated pooled human IgGs from convalescent and vaccinated donors have 5-fold reduced potency  
191 against BA.5 compared to wild-type SARS-CoV-2<sup>26</sup>, such Vax-CCP derivative is devoid of IgA and IgM  
192 nAbs. These findings have important implications if a Vax-CCP program is to be re-launched at the time of  
193 BA.2 and BA.4/5 waves. In particular, the emerging R346X-harboring BA.4.6, BA.4.7, and BA.5.9  
194 sublineages show 1.5-1.9-fold reduction in GMT<sub>50</sub> by BA.1/2 Vax-CCP and 2.4-2.6 reduction by BA.5 Vax-  
195 CCP<sup>27</sup>. Of interest, Vax-CCP after 2 doses remains superior to 4-dose vaccinee plasma in terms of nAb  
196 titers, and Vax-CCP with 3 vaccine doses is not consistently superior to Vax-CCP after 2 vaccine doses<sup>28</sup>.

197 Differences exist among neutralization assay protocols used across studies. These differences are placed  
198 in context once fold-reductions and percent neutralizations are used as reporting measures. The relative  
199 geometric mean titer with minimum and maximum titer levels is an alternative perspective. The live virus  
200 assays can be sorted from the pseudovirus assays along with the minimum and maximum extracted from  
201 the graphs or reported in data from the manuscripts. In general, about 80% of the live virus compared to  
202 pseudovirus overlap in dilutional titer magnitude with the pseudovirus assays outlier measurement  
203 consistently higher in range from a few studies (Figure 6). However, in some cases the minimum reported  
204 is not the limit of detection or quantification, but the lowest number in a group of SARS-CoV-2 antibody  
205 positive participants. Graphical depiction of the minimum and maximum dilutional titers are shown in  
206 Supplementary Figures 1-11.

207

## 208 Discussion

209 Since nAbs are by definition antiviral, CCP with a high nAb GMT<sub>50</sub> is preferable, and there is now strong  
210 clinical evidence that nAb titers correlate with clinical benefit in randomized clinical trials<sup>6,7</sup>. Although  
211 nAb titers correlate with vaccine efficacy<sup>29,30</sup>, it is important to keep in mind that SARS-CoV-2-binding  
212 non-neutralizing antibodies in CCP can similarly provide protection via Fc-mediated functions<sup>31,32</sup>.  
213 However, such functions are harder to measure and no automated assay exists for use in clinical  
214 laboratories. Hence, whereas the presence of a high nAb GMT<sub>50</sub> in CCP is evidence for antibody  
215 effectiveness *in vitro*, the absence of nAb titer does not imply lack of protection *in vivo* where Fc effects  
216 mediate protection by other mechanisms such as antibody-dependent cell-mediated cytotoxicity,  
217 complement activation and phagocytosis.

218 The mechanism by which CCP from vaccinated COVID-19 convalescent individuals better neutralizes  
219 Omicron lineages is probably a combination of higher amounts of nAb and broader antibody specificity.  
220 Higher amounts of antibody could neutralize antigenically different variants through the law of mass  
221 action<sup>33</sup>, whereby even lower affinity antibodies elicited to earlier variants would bind to the Omicron  
222 variant as mass compensates for reduced binding strength to drive the reaction forward. In addition,  
223 vaccinated COVID-19 convalescent individuals would have experienced SARS-CoV-2 protein in two  
224 antigenically different forms: as part of intact infective virions generated *in vivo* during an infectious  
225 process and as antigens in vaccine preparations. As the immune system processes the same antigen in  
226 different forms, there are numerous opportunities for processing the protein in different ways that can  
227 diversify the specificity of the immune response and thus increase the likelihood of eliciting antibodies  
228 that react with variant proteins. Structurally, it has been shown that third dose mRNA vaccination induces  
229 mostly class 1/2 antibodies encoded by IGHV1-58;IGHJ3-1 and IGHV1-69;IGHJ4-1 germlines, but not the  
230 IGHV2-5;IGHJ3-1 germline, i.e. broadly cross-reactive Class 3 antibodies seen after infection<sup>34</sup>.

231 Our analysis provides strong evidence that, unlike what has been observed in Syrian hamster models<sup>35</sup>,  
232 CCP from unvaccinated donors is unlikely (less than 50%) to have any measurable Omicron neutralization.  
233 Although the nAb GMT<sub>50</sub> threshold for clinical utility remains poorly defined, it is noticeable that low BA.1  
234 nAb GMT<sub>50</sub> were generally detected in CCP after infection from pre-Omicron VOCs.

235 However, despite the huge heterogeneity of vaccine schedules, CCP from vaccinated and COVID-19  
236 convalescent individuals (Vax-CCP) consistently harbors high nAb titers against BA.1 and novel  
237 sublineages if collected up to 6 months since last event (either vaccine dose or infection). These Omicron  
238 neutralizing levels are comparable in dilutional titers to that of WA-1 CCP neutralizing WA-1, but their  
239 prevalence is much higher at this time, facilitating recruitment of suitable donors. Pre-Omicron CCP  
240 boosted with WA-1-type vaccines induces heterologous immunity that effectively neutralizes Omicron in  
241 the same assays which rule in or out therapeutic anti-Spike monoclonal antibodies. Consequently,  
242 prescreening of Vax-CCP donors for nAb titers is not necessary, and qualification of Vax-CCP units remains  
243 advisable only within clinical trials. A more objective way to assess previous infection (convalescence)  
244 would be by measuring anti-nucleocapsid (N) antibodies, but unfortunately these vanish quickly<sup>36,37</sup>.  
245 Previous symptomatic infection and vaccination can be established by collecting past medical history  
246 (PMH) during the donor selection visit, which is cheaper, faster, and more reliable than measuring rapidly

247 declining anti-N antibodies. Although there is no formal evidence for this, it is likely that asymptomatic  
248 infection (leading to lower nAb levels in pre-Omicron studies) also leads to lower nAb levels after  
249 vaccination compared to symptomatic infection, given that disease severity correlates with nAb titer<sup>38, 39</sup>;  
250 hence asymptotically infected donors missed by investigating PMH are also less likely to be useful.

251 The same reasoning applies to uninfected vaccinees receiving third dose boosts, but several authorities,  
252 including the FDA, do not currently allow collection from such donors for CCP therapy on the basis that  
253 the convalescent polyclonal and poly-target response is a prerequisite for efficacy and superior to the  
254 polyclonal anti-Spike-only response induced by vaccines. This may be a false premise for recipients of  
255 inactivated whole-virus vaccines (e.g., BBIBP-CorV or VLA2001): for BBIBP-CorV, where efficacy against  
256 Omicron is largely reduced<sup>18, 20, 40</sup>, but the impact of boost doses is still unreported at the time of writing.  
257 Table 1 and Table 9 clearly show that 3-doses of BNT162b2 are enough to restore nAb levels against  
258 Omicron in the absence of SARS-CoV-2 infection.

259 Another point to consider is that information on nAb levels after the third vaccine dose has been almost  
260 exclusively investigated for only 1 month of follow-up, while studies on convalescents extend to more  
261 than 6 months. At present, it seems hence advisable to start from convalescent vaccinees rather than  
262 uninfected 3-dose vaccinees. This is also confirmed by immune escape reported *in vivo* after usage of  
263 vaccine (non-convalescent) plasma<sup>41</sup> despite very high nAb titres, likely due to restricted antigen  
264 specificity. Vaccine schedules with a delayed boost seem to elicit higher and broader nAb levels than the  
265 approved, short schedules<sup>42, 43, 44, 45</sup>, but this remain to be confirmed in larger series. The same is true for  
266 breakthrough infections from Alpha or Delta VOC in fully BNT162b2 vaccinated subjects<sup>46</sup>, although  
267 variation in time from infection due to successive waves is a major confounder.

268 With the increase of Omicron seroprevalence in time, polyclonal intravenous immunoglobulins collected  
269 from regular donors could become a more standardized alternative to CCP, but their efficacy to date (at  
270 the peak of the vaccination campaign) is still 16-fold reduced against Omicron compared to wild-type  
271 SARS-CoV-2<sup>47</sup>, and such preparations include only IgG and not IgM and IgA, which have powerful SARS-  
272 CoV-2 activity<sup>48, 49</sup>. Nevertheless, the FDA recently reported efficacy of hyperimmune serum against  
273 BA.1, BA.2, BA.3, BA.2.12.1, and BA.4/5<sup>50</sup>.

274 CCP collection from vaccinated convalescents (regardless of infecting sublineage, vaccine type and  
275 number of doses) is likely to achieve high nAb titer against VOC Omicron, and, on the basis of lessons  
276 learnt with CCP usage during the first 2 years of the pandemic. Although in ideal situations one would  
277 prefer RCT evidence of efficacy against Omicron before deployment, there is concern that variants are  
278 generated so rapidly that by the time such trials commence this variant could be replaced by another.  
279 Given the success of CCP in 2 outpatient RCTs in reducing disease progression or hospitalization<sup>6, 7</sup> and  
280 the loss of major mAb therapies due to Omicron antigenic changes, the high titers in 2022 omicron CCP  
281 collected from vaccinated convalescents provides an immediate option for COVID-19, especially in LMIC.  
282 Given the reduced hospitalization rate with Omicron compared to Delta<sup>51</sup>, it is even more relevant to  
283 identify patient subsets at risk of progression in order to minimize the number needed to treat to prevent  
284 a single hospitalization. Using the same indications for use of mAb therapies while using the same (now  
285 unused) in-hospital facilities seems a logical approach.

286 We declare we have no conflict of interest related to this manuscript.



287

## 288 References

- 289 1. Ahmed SF, Quadeer AA, McKay M. SARS-CoV-2 T cell responses are expected to remain  
290 robust against Omicron. *Viruses* **14**, 79 (2022).
- 291  
292 2. Bernasconi A, *et al.* Report on Omicron Spike mutations on epitopes and  
293 immunological/epidemiological/kinetics effects from literature. Accessed at  
294 [https://virological.org/t/report-on-omicron-spike-mutations-on-epitopes-and-](https://virological.org/t/report-on-omicron-spike-mutations-on-epitopes-and-immunological-epidemiological-kinetics-effects-from-literature/770)  
295 [immunological-epidemiological-kinetics-effects-from-literature/770](https://virological.org/t/report-on-omicron-spike-mutations-on-epitopes-and-immunological-epidemiological-kinetics-effects-from-literature/770) on July 23, 2022.)  
296 (2021).
- 297  
298 3. Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, Tuccori M. Monoclonal  
299 antibody therapies against SARS-CoV-2. *Lancet Infect Dis*, (2022).
- 300  
301 4. Zhou S, *et al.*  $\beta$ -d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is  
302 Also Mutagenic To Mammalian Cells. *The Journal of Infectious Diseases* **224**, 415-419 (2021).
- 303  
304 5. Jayk Bernal A, *et al.* Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.  
305 *N Engl J Med* **386**, 509-520 (2022).
- 306  
307 6. Libster R, *et al.* Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults.  
308 *N Engl J Med* **384**, 610-618 (2021).
- 309  
310 7. Sullivan D, *et al.* Early Outpatient Treatment for Covid-19 with Convalescent Plasma. *N Engl J*  
311 *Med*, (2021).
- 312  
313 8. Vickers MA, *et al.* Exponential increase in neutralizing and spike specific antibodies following  
314 vaccination of COVID-19 convalescent plasma donors. *Transfusion* **61**, 2099-2106 (2021).
- 315  
316 9. Schmidt F, *et al.* High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape.  
317 *Nature* **600**, 512-516 (2021).
- 318  
319 10. Di Germanio C, *et al.* Vaccination of COVID-19 Convalescent Plasma Donors Increases  
320 Binding and Neutralizing Antibodies Against SARS-CoV-2 Variants. *Transfusion* **62**, 563-569  
321 (2021).
- 322  
323 11. Munro APS, *et al.* Safety and immunogenicity of seven COVID-19 vaccines as a third dose  
324 (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a  
325 blinded, multicentre, randomised, controlled, phase 2 trial. *The Lancet* **398**, 2258-2276  
326 (2021).

- 327  
328 12. Franchini M, *et al.* Neutralizing antibody levels against SARS-CoV-2 variants of concern Delta  
329 and Omicron in vaccine breakthrough-infected blood donors. *Transfusion* **62**, 1171-1176  
330 (2022).
- 331  
332 13. Jacobsen H, *et al.* Diminished neutralization responses towards SARS-CoV-2 Omicron VoC  
333 after mRNA or vector-based COVID-19 vaccinations. 2021.2012.2021.21267898 (2021).
- 334  
335 14. Planas D, *et al.* Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.  
336 *Nature* **602**, 671-675 (2022).
- 337  
338 15. Bekliz M, *et al.* Neutralization of ancestral SARS-CoV-2 and variants Alpha, Beta, Gamma,  
339 Delta, Zeta and Omicron by mRNA vaccination and infection-derived immunity through  
340 homologous and heterologous variants. 2021.2012.2028.21268491 (2021).
- 341  
342 16. Rossler A, Riepler L, Bante D, von Laer D, Kimpel J. SARS-CoV-2 Omicron Variant  
343 Neutralization in Serum from Vaccinated and Convalescent Persons. *N Engl J Med* **386**, 698-  
344 700 (2022).
- 345  
346 17. Muik A, *et al.* Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited  
347 human sera. *Science* **375**, 678-680 (2022).
- 348  
349 18. Zhao X, *et al.* Reduced sera neutralization to Omicron SARS-CoV-2 by both inactivated and  
350 protein subunit vaccines and the convalescents. 2021.2012.2016.472391 (2021).
- 351  
352 19. Dolzhikova IV, *et al.* Sputnik Light booster after Sputnik V vaccination induces robust  
353 neutralizing antibody response to B.1.1.529 (Omicron) SARS-CoV-2 variant.  
354 2021.2012.2017.21267976 (2021).
- 355  
356 20. Bowen JE, *et al.* Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive  
357 panel of human vaccines. 2022.2003.2015.484542 (2022).
- 358  
359 21. Carazo S, *et al.* Protection against Omicron re-infection conferred by prior heterologous  
360 SARS-CoV-2 infection, with and without mRNA vaccination. 2022.2004.2029.22274455  
361 (2022).
- 362  
363 22. Turelli P, *et al.* Omicron infection induces low-level, narrow-range SARS-CoV-2 neutralizing  
364 activity. 2022.2005.2002.22274436 (2022).
- 365  
366 23. Qu P, *et al.* Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants. *N*  
367 *Engl J Med* **386**, 2526-2528 (2022).

- 368  
369 24. Richardson SI, *et al.* SARS-CoV-2 BA.4 infection triggers more cross-reactive neutralizing  
370 antibodies than BA.1. 2022.2007.2014.500039 (2022).
- 371  
372 25. Zhou R, *et al.* Vaccine-breakthrough infection by the SARS-CoV-2 Omicron variant elicits  
373 broadly cross-reactive immune responses. *Clin Transl Med* **2**, e720 (2022).
- 374  
375 26. Aggarwal A, *et al.* SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent  
376 humoral responses and resistance to clinical immunotherapeutics relative to viral variants of  
377 concern. 2022.2007.2007.22277128 (2022).
- 378  
379 27. Jian F, *et al.* Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5  
380 subvariants. 2022.2008.2009.503384 (2022).
- 381  
382 28. Xie X, Zou J, Kurhade C, Liu M, Ren P, Shi P-Y. Neutralization of SARS-CoV-2 Omicron  
383 sublineages by 4 doses of mRNA vaccine. 2022.2007.2029.502055 (2022).
- 384  
385 29. Khoury DS, *et al.* Neutralizing antibody levels are highly predictive of immune protection  
386 from symptomatic SARS-CoV-2 infection. *Nat Med* **27**, 1205-1211 (2021).
- 387  
388 30. Feng S, *et al.* Correlates of protection against symptomatic and asymptomatic SARS-CoV-2  
389 infection. *Nature Medicine* **27**, 2032-2040 (2021).
- 390  
391 31. Gilbert PB, *et al.* Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy  
392 clinical trial. *Science*, eab3435 (2021).
- 393  
394 32. Earle KA, *et al.* Evidence for antibody as a protective correlate for COVID-19 vaccines.  
395 *Vaccine* **39**, 4423-4428 (2021).
- 396  
397 33. Tyrrell DA. Neutralization of viruses by homologous immune serum. II. Theoretical study of  
398 the equilibrium state. *The Journal of experimental medicine* **97**, 863-870 (1953).
- 399  
400 34. Andreano E, *et al.* COVID-19 mRNA third dose induces a unique hybrid immunity-like  
401 antibody response. 2022.2005.2009.491201 (2022).
- 402  
403 35. Ryan KA, *et al.* Convalescence from prototype SARS-CoV-2 protects Syrian hamsters from  
404 disease caused by the Omicron variant. 2021.2012.2024.474081 (2021).
- 405  
406 36. Krutikov M, *et al.* Prevalence and duration of detectable SARS-CoV-2 nucleocapsid  
407 antibodies in staff and residents of long-term care facilities over the first year of the

- 408 pandemic (VIVALDI study): prospective cohort study in England. *The Lancet Healthy*  
409 *Longevity*, (2021).
- 410
- 411 37. Amjadi MF, *et al.* Anti-membrane and anti-spike antibodies are long-lasting and together  
412 discriminate between past COVID-19 infection and vaccination. 2021.2011.2002.21265750  
413 (2021).
- 414
- 415 38. Klein S, *et al.* Sex, age, and hospitalization drive antibody responses in a COVID-19  
416 convalescent plasma donor population. *J Clin Invest* **130**, 6141-6150 (2020).
- 417
- 418 39. Focosi D, Franchini M. Clinical predictors of SARS-CoV-2 neutralizing antibody titers in  
419 COVID-19 convalescents: Implications for convalescent plasma donor recruitment. *European*  
420 *journal of haematology* **107**, 24-28 (2021).
- 421
- 422 40. Yu X, *et al.* Pseudotyped SARS-CoV-2 Omicron variant exhibits significant escape from  
423 neutralization induced by a third booster dose of vaccination. 2021.2012.2017.21267961  
424 (2021).
- 425
- 426 41. Gachoud D, *et al.* Antibody response and intra-host viral evolution after plasma therapy in  
427 COVID-19 patients pre-exposed or not to B-cell depleting agents. 2022.2004.2024.22274200  
428 (2022).
- 429
- 430 42. Chatterjee D, *et al.* SARS-CoV-2 Omicron Spike recognition by plasma from individuals  
431 receiving BNT162b2 mRNA vaccination with a 16-week interval between doses. *Cell Rep* **38**,  
432 110429 (2022).
- 433
- 434 43. Grunau B, *et al.* Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals.  
435 *JAMA* **327**, 279-281 (2022).
- 436
- 437 44. Tauzin A, *et al.* A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector  
438 functions and boost pre-existing humoral and T cell responses. *medRxiv [Preprint]*,  
439 2021.2003.2018.435972 (2021).
- 440
- 441 45. Skowronski DM, *et al.* Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and  
442 extended dosing intervals: test-negative design studies from British Columbia and Quebec,  
443 Canada. *Clin Infect Dis*, ciac290 (2022).
- 444
- 445 46. Miyamoto S, *et al.* Vaccination-infection interval determines cross-neutralization potency to  
446 SARS-CoV-2 Omicron after breakthrough infection by other variants.  
447 2021.2012.2028.21268481 (2022).
- 448

- 449 47. Focosi D, Franchini M. Passive immunotherapies for COVID-19: The subtle line between  
450 standard and hyperimmune immunoglobulins is getting invisible. *Reviews in medical*  
451 *virology*, e2341 (2022).
- 452  
453 48. Klingler J, *et al.* Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2. *J Infect*  
454 *Dis* **223**, 957-970 (2020).
- 455  
456 49. Wang Z, *et al.* Enhanced SARS-CoV-2 neutralization by dimeric IgA. *Sci Transl Med*, (2020).
- 457  
458 50. Awasthi M, Golding H, Khurana S. SARS-CoV-2 hyperimmune intravenous human  
459 immunoglobulins neutralizes Omicron subvariants BA.1, BA.2, BA.2.12.1, BA.3 and BA.4/BA.5  
460 for treatment of COVID-19. *Clinical Infectious Diseases*, (2022).
- 461  
462 51. Wolter N, *et al.* Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant  
463 in South Africa. *Lancet* **399**, 437-446 (2022).
- 464  
465 52. Zeng C, *et al.* Neutralization and Stability of SARS-CoV-2 Omicron Variant. *bioRxiv*, (2021).
- 466  
467 53. Liu L, *et al.* Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2.  
468 *Nature* **602**, 676-681 (2022).
- 469  
470 54. Schmidt F, *et al.* Plasma Neutralization of the SARS-CoV-2 Omicron Variant. *N Engl J Med*  
471 **386**, 599-601 (2022).
- 472  
473 55. Arien KK, *et al.* Three doses of BNT162b2 vaccine confer neutralising antibody capacity  
474 against the SARS-CoV-2 Omicron variant. *NPJ Vaccines* **7**, 35 (2022).
- 475  
476 56. Lusvarghi S, *et al.* SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum,  
477 but evades most convalescent serum and therapeutic antibodies. *Sci Transl Med*, eabn8543  
478 (2022).
- 479  
480 57. Hoffmann M, *et al.* The Omicron variant is highly resistant against antibody-mediated  
481 neutralization: Implications for control of the COVID-19 pandemic. *Cell* **185**, 447-456 e411  
482 (2022).
- 483  
484 58. Zou J, *et al.* Neutralization against Omicron SARS-CoV-2 from previous non-Omicron  
485 infection. *Nat Commun* **13**, 852 (2022).
- 486  
487 59. Zhang L, *et al.* The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron.  
488 *Emerg Microbes Infect* **11**, 1-5 (2022).

- 489  
490 60. Gruell H, *et al.* mRNA booster immunization elicits potent neutralizing serum activity against  
491 the SARS-CoV-2 Omicron variant. *Nat Med* **28**, 477-480 (2022).
- 492  
493 61. Dejnirattisai W, *et al.* SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from  
494 neutralizing antibody responses. *Cell* **185**, 467-484 e415 (2022).
- 495  
496 62. Sheward DJ, *et al.* Variable loss of antibody potency against SARS-CoV-2 B.1.1.529  
497 (Omicron). *bioRxiv*, 2021.2012.2019.473354 (2021).
- 498  
499 63. Tada T, *et al.* Increased resistance of SARS-CoV-2 Omicron variant to neutralization by  
500 vaccine-elicited and therapeutic antibodies. *EBioMedicine* **78**, 103944 (2022).
- 501  
502 64. Aggarwal A, *et al.* SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance  
503 to clinical immunotherapeutics relative to viral variants of concern. *medRxiv*,  
504 2021.2012.2014.21267772 (2021).
- 505  
506 65. Zhao X, *et al.* Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant. *N*  
507 *Engl J Med* **386**, 894-896 (2022).
- 508  
509 66. Bowen JE, *et al.* Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive  
510 panel of human vaccines. *bioRxiv*, (2022).
- 511  
512 67. Carreno JM, *et al.* Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron.  
513 *Nature* **602**, 682-688 (2022).
- 514  
515 68. Syed AM, *et al.* Omicron mutations enhance infectivity and reduce antibody neutralization of  
516 SARS-CoV-2 virus-like particles. *medRxiv*, (2022).
- 517  
518 69. Haveri A, *et al.* Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA  
519 vaccination in health care workers and elderly subjects. *Eur J Immunol*, (2022).
- 520  
521 70. Li M, *et al.* Convalescent plasma with a high level of virus-specific antibody effectively  
522 neutralizes SARS-CoV-2 variants of concern. *Blood Adv*, 2022.2003.2001.22271662 (2022).
- 523  
524 71. Kurahashi Y, *et al.* Cross-neutralizing activity against Omicron could be obtained in SARS-  
525 CoV-2 convalescent patients who received two doses of mRNA vaccination. *medRxiv*,  
526 2022.2002.2024.22271262 (2022).
- 527

- 528 72. Lechmere T, *et al.* Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following  
529 Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals. *mBio* **13**, e0379821  
530 (2022).
- 531  
532 73. Edara VV, *et al.* mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing  
533 activity against the SARS-CoV-2 omicron variant. *Cell Rep Med* **3**, 100529 (2022).
- 534  
535 74. Cele S, *et al.* Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization.  
536 *Nature* **602**, 654-656 (2022).
- 537  
538 75. Wilhelm A, *et al.* Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera  
539 and Monoclonal Antibodies. *medRxiv*, 2021.2012.2007.21267432 (2021).
- 540  
541 76. Doria-Rose NA, *et al.* Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron  
542 Neutralization. *medRxiv*, 2021.2012.2015.21267805 (2021).
- 543  
544 77. Kawaoka Y, *et al.* Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2.  
545 *Res Sq*, (2022).
- 546  
547 78. Dejnirattisai W, *et al.* Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by  
548 post-immunisation serum. *Lancet* **399**, 234-236 (2022).
- 549  
550 79. Wang Q, *et al.* Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and  
551 BA.5. *Nature*, (2022).
- 552  
553 80. Khan K, *et al.* Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection.  
554 *Nat Commun* **13**, 4686 (2022).
- 555  
556 81. Muik A, *et al.* Omicron BA.2 breakthrough infection enhances cross-neutralization of  
557 BA.2.12.1 and BA.4/BA.5. 2022.2008.2002.502461 (2022).
- 558  
559 82. Planas D, *et al.* Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2  
560 vaccinated individuals, with or without Omicron breakthrough infection.  
561 2022.2007.2022.22277885 (2022).
- 562  
563 83. Yu J, *et al.* Comparable Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants.  
564 2022.2002.2006.22270533 (2022).
- 565  
566 84. Tuekprakhon A, *et al.* Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine  
567 and BA.1 serum. *Cell* **185**, 2422-2433.e2413 (2022).

568

569 85. Hachmann NP, *et al.* Neutralization Escape by the SARS-CoV-2 Omicron Variants BA.2.12.1  
570 and BA.4/BA.5. *N Engl J Med* **387**, 86-88 (2022).

571

572


573



574 **Figure 1**

575 PRISMA flowchart for the current study.

576




577

578

579

## Figure 2

580 Geometric mean neutralizing titers ( $GMT_{50}$ ) against WA-1 versus Omicron BA.1 by study for A)  
 581 unvaccinated convalescent plasma and B) vaccinated plasma with or without COVID-19. Geomeans for  
 582 entire study groups with neutralization of WA-1 in filled circles and of Omicron BA.1 in empty circles with  
 583 geomeans, fold reduction (FR) above data, and number of studies above x-axis. All geomeans are not  
 584 statistically significant in difference by multiple comparison in Tukey's test.



585

586


587

588

589

590 **Figure 3**

591 Percent of individual plasma samples in each study showing any titer of Omicron BA.1 neutralization. The  
 592 percent of samples within a study condition which neutralized Omicron BA.1 graphed in increasing  
 593 percentages with the number of samples tested on the right y axis. A) pre-Alpha CCP neutralization of  
 594 Omicron BA.1; B) Alpha, Beta and Delta CCP neutralization of Omicron BA.1 C) 2 dose mRNA vaccines  
 595 neutralization of Omicron BA.1 D) post-COVID-19/post-vaccine (Vax-CCP) and uninfected 3-dose vaccine  
 596 neutralization of Omicron BA.1.



597

598

599

600

601


602

603

604

## Figure 4

605 Geometric mean neutralizing titers ( $GMT_{50}$ ) of anti-WA.1 or anti-Omicron BA.1 neutralizing antibodies in  
 606 plasma samples from 5 studies investigating diverse SARS-CoV-2 infecting lineage or vaccination status. 5  
 607 studies characterized A) pre-Alpha, Alpha, Beta and Delta CCP for Omicron BA.1 nAb compared to WA-1,  
 608 and also B) 2 or 3 doses BNT162b2 plasma, as well as post-COVID-19 plus BNT162b vaccine (Vax-CCP). C) 9  
 609 additional studies looked at the same vaccine conditions in the first 5 comparing WA-1 nAb to Omicron  
 610 BA.1 nAb.




611


## 612 Figure 5

613 Geometric mean neutralizing titers (GMT<sub>50</sub>) against WA-1 versus Omicron BA.1, BA.2 or BA.4/5 for A)  
 614 boosted vaccinated plasma with or without BA.1 COVID-19 and B) unvaccinated preomicron or BA.1 CCP.  
 615 Geomeans for entire study groups with neutralization of WA-1 in filled circles with Omicron in empty  
 616 circles with geomeans and fold reduction (FR) above data and number of studies above x-axis. All  
 617 geomeans are not statistically significant in difference by multiple comparison in Tukey's test. The  
 618 percent of samples within a study condition which neutralized Omicron graphed in increasing  
 619 percentages with the number of samples tested on the right y axis. C) uninfected 3-dose vaccine  
 620 neutralization of Omicron BA.1, BA.2 and BA.4/5.; D) post-COVID-19-BA.1/post-vaccine (Vax-CCP).


A




B



C



D




621

622

## 623 Figure 6

624 GMT<sub>50</sub> from each study with minimum and maximum dilution titer also shown. Live virus assays are on  
 625 the left and pseudoviral assays on the right. A) pre-alpha CCP against WA-1, B) post COVID-19/Vax  
 626 against WA-1. C) 3 dose BNT 162b2 against WA-1, D) post COVID-19 BA.1/Vac against WA-1, E) pre-alpha  
 627 CCP against omicron BA.1, F) post COVID-19/Vax against Omicron BA.1. G) 3 dose BNT 162b2 against  
 628 Omicron BA.1, H) post COVID-19 BA.1/Vac against Omicron BA.1, I) post COVID-19 BA.1/Vac against  
 629 Omicron BA.2 J) post COVID-19 BA.1/Vac against BA.4/5.



630

631

632 **Table 1**

633 Comparison of WA-1 to Omicron BA.1 nAb and percent with any Omicron BA.1 nAb amongst VOC CCP  
 634 and vaccination status.

plasma type	number of studies	WA-1 nAb GMT <sub>50</sub>	Omicron BA1 nAb GMT <sub>50</sub>	fold reduction in nAb GMT <sub>50</sub> vs. Omicron BA.1	total number individuals in all studies	total Omicron BA.1 neutralizing number	Omicron BA.1 neutralizing percent
pre-Alpha	27	311	15	20	707	315	45
Alpha	6	301	6	50	64	21	33
Beta	5	91	8	11	37	19	51
Delta	7	464	42	11	94	69	73
2 dose BNT162b2 plasma	22	628	27	24	432	202	47
2 dose mRNA-1273 plasma	9	686	20	35	134	81	60
post-COVID-19/full vacc plasma	19	2753	192	14	279	243	87
3 dose BNT162b2 plasma	17	2588	290	9	310	286	92

635

636 **Table 2**

637 Efficacy of CCP, vaccinee plasma and Vax-CCP expressed as GMT<sub>50</sub> against Omicron sublineages.

plasma type	number of studies	WA-1 nAb GMT <sub>50</sub>	Omicron BA.1 nAb GMT <sub>50</sub> (Fold reduction from WA-1)	Omicron BA.2 nAb GMT <sub>50</sub> (Fold reduction from WA-1)	Omicron BA.14/5 nAb GMT <sub>50</sub> (Fold reduction from WA-1)	total number individuals in all studies	Omicron BA.1; BA.2; BA.4/5 neutralizing percent
Pre-omicron CCP	3	1338	133 (10 FR)	132 (10 FR)	177 (8 FR)	50	35; 37;40
BA.1 CCP	3	71	366 (0.16 FR)	180 (0.4 FR)	82 (1 FR)	74	66; 80; 76
BA.4/5 CCP	1	904	557 (2 FR)	884 (1 FR)	1047 (1 FR)	13	100; 100; 100
3 dose BNT162b2 plasma	8	3247	494 (7 FR)	511 (6 FR)	189 (16 FR)	159	97; 98; 96
post-COVID-19-BA.1/full vacc plasma	11	3578	1713 (2 FR)	1830 (2 FR)	454 (8 FR)	142	99; 99; 99

638



## 639 Supplementary table 1

640 Synopsis of 27 *in vitro* studies investigating the efficacy of pre-Alpha CCP against Omicron

641

reference	Assay type (live virus =1 Pseudovirus=2)	time mean or median (min-max)	(pre-Alpha CCP) WA-1 GMT <sub>50</sub>	(pre-Alpha CCP) BA.1 GMT <sub>50</sub>	(pre-Alpha CCP) fold drop vs. BA.1	(pre-Alpha CCP) number in study	(pre-Alpha CCP) BA.1 neutralizing number	(pre-Alpha CCP) BA.1 neutralizing percent
Zeng <sup>52</sup>	2	(1-2) mo	1712	14	122	9	1	11
Liu <sup>53</sup>	2	(9-120) days	4344	135	32	10	2	20
Schmidt <sup>54</sup>	2	1.2 mo	2616	68	38	20	19	95
Schmidt <sup>54</sup>	2	12 mo	2037	136	15	20	17	85
Schmidt <sup>54</sup>	2	6 mo	1678	34	49	20	13	65
Arien <sup>55</sup>	1	1 mo	1086	50	22	10	1	10
Lusvarghi <sup>56</sup>	2	30 (14-51) days	715	25	29	16	2	13
Hoffman <sup>57</sup>	2	< 2 mo	614	8	77	17	8	47
Zou <sup>58</sup>	1	1 mo	601	38	16	64	41	64
Planas <sup>14</sup>	2	6 mo	569	28	20	16	6	38
Planas <sup>14</sup>	2	12 mo	580	29	20	23	8	35
Zhang <sup>59</sup>	2	(1-3) mo	556	66	8	28	28	100
Gruel <sup>60</sup>	2	1.5 mo	494	6	82	30	3	10
Gruel <sup>60</sup>	2	12 mo	93	8	12	30	9	30
Dejnirattisai <sup>61</sup>	1	42 med days	475	28	17	32	32	100
Sheward <sup>62</sup>	2	1 mo	350	40	9	34	25	74
Tada <sup>63</sup>	2	(32-57)	233	9	26	10	4	40
Aggerwal <sup>64</sup>	1	1+ mo	215	10	22	20	0	0
Zhao <sup>65</sup>	2	18 (11-51) days	193	11	17	16	1	6
Bowen <sup>66</sup>	2	(28-78) days	162	10	16	28	13	46
Zou <sup>58</sup>	1	6 mo	142	32	4	36	30	83
Carreno <sup>67</sup>	1	58 (23-87) days	67	6	11	15	4	27
Syed <sup>68</sup>	2	<1 mo	80	20	4	8	6	75
Bekliz <sup>15</sup>	1	(3-137) days	37	1	45	34	5	15
Haveri <sup>69</sup>	1	1 mo	32	2	16	13	0	0
Li <sup>70</sup>	1	<1 mo	28	2	14	108	22	22
Kurahashi <sup>71</sup>	1	(1-3) mo	19	2	13	40	15	38
GM (GMT <sub>50</sub> )			1712	15	20			
Total (AVG%)						707	315	(45%)

642

643 **Supplementary table 2**

644 Synopsis of 5 *in vitro* studies investigating the efficacy of Alpha CCP against Omicron

reference	Assay type (live virus =1 Pseudovirus=2 )	time mean or media n (min- max)	(Alph a CCP) WA-1 GMT <sub>50</sub>	(Alph a CCP) BA.1 GMT <sub>50</sub>	(Alpha CCP) fold reductio n vs. BA.1	(Alpha CCP) numbe r	(Alpha CCP) BA.1 neutralizin g number	(Alpha CCP) BA.1 neutralizin g percent
Lusvarghi <sup>56</sup>	2	30 (14- 51) days	4978	30	166	4	1	25
Dejnirattisai <sup>61</sup>	1	19 med days	1313	39	34	18	18	100
Rossler <sup>16</sup>	1		256	4	63	10	0	0
Haveri <sup>69</sup>	1	1 mo	32	2	16	20	0	0
Bekliz <sup>15</sup>	1	3-137 days	46	1	57	12	2	17
GM (GMT <sub>50</sub> )			301	6	50			
Total (AVG%)						64	21	(33%)

645

646

## 647 Supplementary table 3

648 Synopsis of 5 *in vitro* studies investigating the efficacy of Beta CCP against Omicron.

reference	Assay type (live virus =1 Pseudovirus=2 )	time mean or media n (min- max)	(beta CCP) WA-1 GMT <sub>50</sub>	(beta CCP) BA.1 GMT <sub>50</sub>	(beta CCP) fold reductio n vs. BA.1	(beta CCP) numbe r	(beta CCP) BA.1 neutralizin g number	(beta CCP) BA.1 neutralizin g percent
Lusvarghi <sup>56</sup>	2	30 (14- 51) days	439	191	2	2	2	100
Dejnirattisai <sup>61</sup>	1	61 med days	327	28	12	14	14	100
Rossler <sup>16</sup>	1		128	4	32	8	1	13
Haveri <sup>69</sup>	1	1 mo	16	2	8	5	0	0
Bekliz <sup>15</sup>	1	3-137 days	21	1	23	8	2	25
GM (GMT <sub>50</sub> )			140	8	11			
Total (AVG%)						37	19	(51%)

649

650 **Supplementary table 4**

651 Synopsis of 7 *in vitro* studies investigating the efficacy of Delta CCP against Omicron.

reference	Assay type (live virus =1 Pseudovirus=2)	time mean or median (min- max)	(Delta CCP) WA-1 GMT <sub>50</sub>	(Delta CCP) BA.1 GMT <sub>50</sub>	(Delta CCP) fold drop vs. BA.1	(Delta CCP) number	(Delta CCP) BA.1 neutralizing number	(Delta CCP) BA.1 neutralizing percent
Zeng <sup>52</sup>	2	(1-2) mo	11200	3476	3	19	10	53
Lechmere <sup>72</sup>	2	(13-22) days	668	164	4	14	12	86
Lusvarghi <sup>56</sup>	2	30 (14- 51) days	1211	18	66	15	12	80
Aggerwal <sup>64</sup>	1		770	37	21	10	9	90
Rosler <sup>16</sup>	1		192	8	25	7	1	14
Bekliz <sup>15</sup>	1	3-137 days	73	3	24	10	6	60
Dejnirattisai <sup>61</sup>	1	38 med dayas	47	27	2	19	19	100
GM (GMT <sub>50</sub> )			167	10	17			
Total (AVG%)						94	69	(73%)

652

## 653 Supplementary table 5

654 Synopsis of 22 *in vitro* studies investigating the efficacy of plasma from uninfected recipients of 2  
655 BNT162b2 doses against Omicron.

reference	Assay type (live virus =1 Pseudo virus=2)	time mean or median (min-max)	(2 dose BNT162 b2 plasma) WA-1 GMT <sub>50</sub>	(2 dose BNT162 b2 plasma) BA.1 GMT <sub>50</sub>	(2 dose BNT162 b2 plasma) fold reduction vs. BA.1	(2 dose BNT162 b2 plasma) number	(2 dose BNT162b 2 plasma) BA.1 neutralizing number	(2 dose BNT162b 2 plasma) BA.1 neutralizing percent
Schmidt <sup>54</sup>	2	1 mo	7627	92	83	18	15	83
Liu <sup>53</sup>	2	(16-213) days	4669	222	21	13	6	46
Zeng <sup>52</sup>	2	(21-28) days	2769	121	23	48	13	27
Schmidt <sup>54</sup>	2	5 mo	2435	126	19	18	15	83
Dejnirattisai <sup>61</sup>	1	1 mo	1993	19	105	20	20	100
Chatterjee <sup>42</sup>	2	4 mo	1544	935	2	25	25	100
Syed <sup>68</sup>	2	1-1.5 mo	1280	80	16	21	14	67
Tada <sup>63</sup>	2	90 days	859	25	34	9	7	78
Bowen <sup>66</sup>	2	9-20 days	764	28	27	10	9	90
Chatterjee <sup>42</sup>	2	1 mo	641	105	6	19	10	53
Hoffman <sup>57</sup>	2	<3 mo	604	10	60	11	1	9
Lusvarghi <sup>56</sup>	2	30 (28-34) days	562	22	26	39	3	8
Gruell <sup>60</sup>	2	1 mo	546	8	68	30	10	33
Rossler <sup>16</sup>	1	1 mo	512	24	21	20	9	45
Edara <sup>73</sup>	1	(14-28) days	384	20	19	13	2	15
Muik <sup>17</sup>	1	1 mo	368	6	61	25	8	32
Cele <sup>74</sup>	1	(10-48) days	263	12	22	8	5	83
Bekliz <sup>15</sup>	1	1 mo	338	4	86	16	11	69
Planas <sup>14</sup>	2	161 (138-176) days	329	30	11	16	1	6
Carreno <sup>67</sup>	1	18 (14-21) days	274	11	25	10	7	70
Gruell <sup>60</sup>	2	5 mo	139	9	15	30	11	37
Wilheim <sup>75</sup>	1	6 mo	6	1	6	15	0	0
GM (GMT <sub>50</sub> )			628	27	24			
Total (AVG%)						432	202	(47%)

656

657 **Supplementary table 6**

658 Synopsis of 9 *in vitro* studies investigating the efficacy of plasma from uninfected recipients of 2 mRNA-  
659 1273 doses against Omicron.

reference	Assay type (live virus =1 Pseudovirus=2)	time mean or median (min- max)	(2 dose mRNA- 1273 plasma) WA-1 GMT <sub>50</sub>	(2 dose mRNA- 1273 plasma) BA.1 GMT <sub>50</sub>	(2 dose mRNA- 1273 plasma) fold drop vs. BA.1	(2 dose mRNA- 1273 plasma) number	(2 dose mRNA- 1273 plasma) BA.1 neutralizing number	(2 dose mRNA- 1273 plasma) BA.1 neutralizing percent
Doria-Rose <sup>76</sup>	2	1 mo	3016	62	49	30	22	73
Syed <sup>68</sup>	2	1-1.5 mo	2560	320	8	10	8	80
Doria-Rose <sup>76</sup>	2	1 mo	2269	27	84	30	22	73
Bowen <sup>66</sup>	2	6-15 days	1155	26	44	11	9	82
Tada <sup>63</sup>	2	80 days	999	38	26	8	5	63
Edara <sup>73</sup>	1	1 mo	745	15	50	11	4	36
Carreno <sup>67</sup>	1	26 (14- 36) days	581	14	42	10	10	100
Rosler <sup>16</sup>	1	5 mo	384	8	48	10	1	10
Wilheim <sup>75</sup>	1	6 mo	10	1	20	14	0	0
GM (GMT <sub>50</sub> )			644	21	31			
Total (AVG%)						134	81	(60%)

660

661 **Supplementary table 7**

662 Synopsis of 17 *in vitro* studies investigating the efficacy of plasma from infected and vaccinated (2  
663 BNT162b2 doses) subjects (Vax-CCP) against Omicron.

reference	Assay type (live virus =1 Pseudovirus=2)	time mean or median (min-max)	(post-COVID-19/full vacc plasma) WA-1 GMT <sub>50</sub>	(post-COVID-19/full vacc plasma) BA.1 GMT <sub>50</sub>	(post-COVID-19/full vacc plasma) fold drop vs. BA.1	(post-COVID-19/full vacc plasma) number	(post-COVID-19/full vacc plasma) BA.1 neutralizing number	(post-COVID-19/full vacc plasma) BA.1 neutralizing percent
Schmidt <sup>54</sup>	2	1 mo	388872	8106	48	17	17	100
Planas <sup>14</sup>	2	32 (21-48) days	78162	1475	53	22	22	100
Tada <sup>63</sup>	2	1 mo	14868	921	16	7	7	100
Cele <sup>74</sup>	1	(18-63)	6763	305	22	13	13	100
Kawoaka <sup>77</sup>	1	1 mo	10002	2029	5	13	13	100
Kawoaka <sup>77</sup>	1	3 mo	2251	399	6	13	13	100
Gruell <sup>60</sup>	2	1.5 mo	7997	1599	5	30	30	100
Arien <sup>55</sup>	1		4822	236	20	10	10	100
Carreno <sup>67</sup>	1	26 (15-39) days	2000	146	14	10	10	100
Dejnirattisai <sup>61</sup>	1	1 mo	1899	215	9	17	17	100
Li <sup>70</sup>	1	< 1 mo	1598	80	20	20	20	100
Bekliz <sup>15</sup>	1	1 mo	1190	65	18	6	6	100
Haveri <sup>69</sup>	1	1 mo	1024	32	32	33	33	100
Rosler <sup>16</sup>	1		1024	256	4	5	5	100
Edara <sup>73</sup>	1	6 mo	625	31	20	24	15	63
Kurahashi <sup>71</sup>	1	1 mo	21	2	14	19	7	37
Wilheim <sup>75</sup>	1	(.07-7.6) mo	100	10	10	20	5	25
GM (GMT <sub>50</sub> )			2753	192	14			
Total (AVG%)						279	243	(87%)

664

## 665 Supplementary table 8

666 Synopsis of 17 *in vitro* studies investigating the efficacy of plasma from uninfected subjects vaccinated  
667 with 3 BNT162b2 doses against Omicron.

reference	Assay type (live virus =1 Pseudovirus=2)	time mean or median (min-max)	(3 dose BNT162b2 plasma) WA-1 GMT <sub>50</sub>	(3 dose BNT162b2 plasma) BA.1 GMT <sub>50</sub>	(3 dose BNT162b2 plasma) fold drop vs. BA.1	(3 dose BNT162b2 plasma) number	(3 dose BNT162b2 plasma) BA.1 neutralizing number	(3 dose BNT162b2 plasma) BA.1 neutralizing percent
Schmidt <sup>54</sup>	2	1 mo	65617	3871	17	18	18	100
Planas <sup>14</sup>	2	33 (8-61) days	12739	722	18	20	20	100
Zeng <sup>52</sup>	2	(21-28) days	10412	3179	3	23	20	87
Dejnirattisai <sup>61</sup>	1	1 mo	9219	649	14	20	20	100
Gruell <sup>60</sup>	2	1 mo	6241	1248	5	30	30	100
Lusvarghi <sup>56</sup>	2	43 (7-93) days	5029	718	7	39	39	100
Tada <sup>63</sup>	2	1 mo	4892	360	14	12	12	100
Liu <sup>53</sup>	2	(14-90) days	4673	715	7	15	15	100
Kawoaka <sup>77</sup>	1	1 mo	2866	485	6	10	10	100
Arien <sup>55</sup>	1		2157	165	13	10	10	100
Hoffman <sup>57</sup>	2	<1 mo	2006	305	7	10	9	90
Edara <sup>73</sup>	1	(17-28) days	1247	89	14	35	31	89
Carreno <sup>67</sup>	1	19 (14-28) days	710	94	8	10	10	100
Syed <sup>68</sup>	2	1-1.5 mo	960	160	6	8	8	100
Muik <sup>17</sup>	1	1 mo	673	106	6	28	27	96
Haveri <sup>69</sup>	1	(21-42) days	256	16	16	7	7	100
Wilheim <sup>75</sup>	1	3 mo	100	10	10	15	0	0
GM (GMT <sub>50</sub> )		time mean or median (min-max)	2588	290	9			
Total (AVG%)						310	286	(92%)



## 668 Supplementary table 9

669 Synopsis of *in vitro* studies investigating the efficacy of plasma from uninfected subjects vaccinated with  
 670 3 doses of mRNA-1273, AZD-1222 or Ad26.COV2 against BA.1. Because of diversity of vaccines the  
 671 geomeans and sums were not computed.

672

reference	vaccine type	WA-1 GMT <sub>50</sub>	fold drop vs. BA.1	BA.1 GMT <sub>50</sub>	number	BA.1 neutralizing number	BA.1 neutralizing percent
Careno <sup>67</sup>	COVID19 + mRNA-1273	3000	11	272	10	10	100
Edara <sup>73</sup>	COVID19 + mRNA-1273 6 mo	931	25	38	13	9	69
Careno <sup>67</sup>	3 dose mRNA-1273	1000	17	60	10	10	100
Doria-Rose <sup>76</sup>	3 dose mRNA-1273	8457	4	2002	30	30	100
Doria-Rose <sup>76</sup>	3 dose mRNA-1273	4216	6	650	30	30	100
Edara <sup>73</sup>	3 dose mRNA-1273	1395	15	96	17	16	94
Dejnirattisai <sup>78</sup>	AZD1222	390	19	21	41	41	100
Rosler <sup>16</sup>	AZD1222	250	25	10.0	20	0	0
Planas <sup>14</sup>	AZD1222 5 mo	187	18	10	18	2	10
Syed <sup>58</sup>	Ad26.COV2	28	1	20.0	9	2	22
Schmidt <sup>54</sup>	Ad26.COV2 1 mo	588	24	25	19	2	11
Schmidt <sup>54</sup>	Ad26.COV2 6 mo	982	23	43	19	11	58

673

## 674 Supplementary table 10

675 Synopsis of *in vitro* studies investigating the efficacy of plasma from (pre-omicron, BA.1 and BA.4/5 CCP)

676 subjects against Omicron BA.1, BA.2 and BA.4/5.

reference	Assay type (live virus =1 Pseudovirus =2)	time mean or median (min-max)	WA-1 nAb GMT <sub>50</sub>	Omicron BA.1 nAb GMT <sub>50</sub> (Fold reduction from WA-1)	Omicron BA.2 nAb GMT <sub>50</sub> (Fold reduction from WA-1)	Omicron BA.14/5 nAb GMT <sub>50</sub> (Fold reduction from WA-1)	Number in study	BA.1; BA.2; BA.4/5 neutralizing number	BA.1; BA.2; BA.4/5 neutralizing percent
preomicron									
Wang <sup>79</sup>	1	(7-213) days	5185	845 (6 FR)	939 (6 FR)	596 (9 FR)	22	22; 22;22	100;100 ; 100
Awasthi <sup>50</sup>	2	>1 mo	130	13 (10 FR)	12 (11 FR)	13 (13 FR)	10	1; 1; 1	10; 10; 10
Qu <sup>23</sup>	2	3 day post hosp.	3554	214 (17 FR)	205	717 (5 FR)	18	12; 14; 17	67; 78; 94
GM (GMT <sub>50</sub> )			1338	133 (10 FR)	132 (10 FR)	177 (8 FR)			
Total (AVG%)							50	35; 37;40	(70;74; 80)
BA.1									
Khan <sup>80</sup>	1	23 (19-27iqr)	Not done	275	Not done	36	24	24; nd; 18	100;nd; 75
Zou <sup>58</sup>	1	25 (13-62) days	16	445 (0.04 FR)	107 (0.15 FR)	Not done	20	20; 19; nd	100;95; nd
Qu <sup>23</sup>	2	1-8 days post hosp.	317	399 (0.8 FR)	304 (1.04 FR)	189 (2 FR)	30	22; 21; 23	73;70;77
GM (GMT <sub>50</sub> )			71	366 (0.16 FR)	180 (0.4 FR)	82 (1 FR)	74		
Total (AVG%)								66;40;41	89;80;93
BA.4/5									
Richards <sup>24</sup>	2	< 9 days into hosp.	904	557 (2 FR)	884 (1 FR)	1047 (1 FR)	13	13;13;13	100;100 ; 100

677

## 678 Supplementary table 11

679 Synopsis of *in vitro* studies investigating the efficacy of plasma from (post-COVID-19-BA.1/full vacc  
 680 plasma) subjects (Vax-CCP) against Omicron BA.1, BA.2 and BA.4/5.

reference	Assay type (live virus =1 Pseudovirus= 2)	time mean or media n (min- max)	WA-1 nAb GMT <sub>50</sub>	Omicron BA.1 nAb GMT <sub>50</sub> (Fold reductio n from WA-1)	Omicron BA.2 nAb GMT <sub>50</sub> (Fold reductio n from WA-1)	Omicron BA.14/5 nAb GMT <sub>50</sub> (Fold reductio n from WA-1)	Numbe r in study	BA.1; BA.2; BA.4/5 neutralizin g number	BA.1; BA.2; BA.4/5 neutralizin g percent
Muik <sup>81</sup> (BA.1)	1	43 (25- 55)	780	656 (1 FR)	800 (1 FR)	156 (5 FR)	14	14;14;13	100;100;9 3
Muik <sup>81</sup> (BA.2)	1	39 (30- 99)	531	347 (2 FR)	545 (1 FR)	209 (3 FR)	13	13;13;13	100;100; 100
Khan <sup>80</sup>	1		2038	507 (4 FR)		158 (13 FR)	15	15;nd;15	100;nd; 100
Wang <sup>79</sup> (BA.1)	1	(14- 135) days	9500	2406 (4 FR)	2052 (5 FR)	473 (20 FR)	13	13;13;13	100;100; 100
Wang <sup>79</sup> (BA.2)	1	(14- 36) days	9527	3054 (3 FR)	3679 (3 FR)	1627 (6 FR)	12	12;12;12	100;100; 100
Planas <sup>82</sup>	1	80 med days	1000 0	7000 (1 FR)	9000 (1 FR)	1000 (10 FR)	11	11;11;11	100;100; 100
Awasthi <sup>50</sup>	2	>1 mo	1120	733 (2 FR)	380 (3 FR)	76 (15 FR)	6	6;6;6	100;100; 100
Yu <sup>83</sup>	2	14 med days	4046	3249 (1 FR)	2448 (2 FR)		8	7;7;nd	88;88;nd
Richardson <sup>24</sup>	2	< 9 days into hosp.	5484	4244 (1 FR)	3779 (1 FR)	1984 (3 FR)	9	9;9;9	100;100; 100
Tuekprakhon <sup>84</sup>	2	45 med days	5861	3563 (2 FR)	2119 (3 FR)	1064 (6 FR)	14	14;14;14	100;100; 100
Hachman <sup>85</sup>	2	29 (2- 113) days	1105 0	1740 (6 FR)	1910 (6 FR)	590 (19 FR)	27	27;27;27	100;100; 100
GM (GMT <sub>50</sub> )			3578	1713 (2 FR)	1830 (2 FR)	454 (8 FR)			
Total (AVG%)							142	141; 126; 133	99;99;99

681

682 **Supplementary table 12**

683 Synopsis of *in vitro* studies investigating the efficacy of plasma from (3 dose BNT162b2 plasma) subjects  
 684 against Omicron BA.1, BA.2 and BA.4/5.


reference	Assay type (live virus =1 Pseudovirus= 2)	time mean or media n (min- max)	WA-1 nAb GMT <sub>50</sub>	Omicron BA.1 nAb GMT <sub>50</sub> (Fold reductio n from WA-1)	Omicron BA.2 nAb GMT <sub>50</sub> (Fold reductio n from WA-1)	Omicron BA.14/5 nAb GMT <sub>50</sub> (Fold reductio n from WA-1)	Numbe r in study	BA.1; BA.2; BA.4/5 neutralizin g number	BA.1; BA.2; BA.4/5 neutralizin g percent
Planas <sup>82</sup>	1	132 med days	2000	140 (14 FR)	100 (20 FR)	50 (40 FR)	22	19;20;19	86;91;86
Muik <sup>81</sup>	1	28 (26- 30)	549	90 (6 FR)	93 (6 FR)	37 (15 FR)	18	17;18; 17	94;100;94
Khan <sup>80</sup>	1		4123	208 (20 FR)	Not done	211 (20 FR)	18	18;nd;;18	100;nd; 100
Wang <sup>79</sup>	1	(14- 90) days	6657	130 (5 FR)0	1461 (5 FR)	347 (19 FR)	16	16;16;14	100;100; 88
Qu <sup>23</sup>	2	(21- 28) days	2633	976 (3 FR)	933 (3 FR)	647 (4 FR)	15	14;14;15	93;93; 100
Tuekprakhon <sup>84</sup>	2	28 days	4122	1116 (4 FR)	1113 (4 FR)	360 (11 FR)	19	19;19;19	100;100; 100
Hachman <sup>85</sup>	2	14 days	5783	900 (6 FR)	829 (7 FR)	275 (21 FR)	27	27;27;27	100;100; 100
Yu <sup>83</sup>	2	14 days	6539	1066 (6 FR)	776 (8 FR)	Not done	24	24;24	100;100; nd
GM (GMT <sub>50</sub> )			3247	494 (7 FR)	511 (6 FR)	189 (16 FR)	1		
Total (AVG%)							159	154;138;12 9	97;98;96

685

686

## 687 Supplementary Figure 1

688 Alternative graphing of Supplementary table 1 and Figure 2A. 27 *in vitro* studies investigating the efficacy  
 689 of pre-Alpha CCP against Omicron with GMT<sub>50</sub> from each study with minimum and maximum dilution  
 690 titer also shown. The absolute values are graphed in the upper panels for WA-1 on left and omicron on  
 691 right. In the lower panels all numbers divided by the minimum value for each study to normalize for WA-  
 692 1 on left and Omicron on right. The GMT<sub>50</sub> approximates 10 with this computational division. Live virus  
 693 assays are on the left and pseudoviral assays on the right.



694

695

696


697

698

## 699 Supplementary Figure 2

700 Alternative graphing of Supplementary table 2 and Figure 2A. 5 *in vitro* studies investigating the efficacy  
 701 of Alpha CCP against Omicron with GMT<sub>50</sub> from each study with minimum and maximum dilution titer  
 702 also shown. The absolute values are graphed in the upper panels for WA-1 on left and omicron on right.  
 703 In the lower panels all numbers divided by the minimum value for each study to normalize for WA-1 on  
 704 left and Omicron on right. The GMT<sub>50</sub> approximates 10 with this computational division. Live virus assays  
 705 are on the left and pseudoviral assays on the right.

706




707

708

709

## 710 Supplementary Figure 3

711 Alternative graphing of Supplementary table 3 and Figure 2A. 5 *in vitro* studies investigating the efficacy  
712 of Beta CCP against Omicron with GMT<sub>50</sub> from each study with minimum and maximum dilution titer also  
713 shown. The absolute values are graphed in the upper panels for WA-1 on left and omicron on right. In the  
714 lower panels all numbers divided by the minimum value for each study to normalize for WA-1 on left and  
715 Omicron on right. The GMT<sub>50</sub> approximates 10 with this computational division. Live virus assays are on  
716 the left and pseudoviral assays on the right.




717

718

## 719 Supplementary Figure 4

720 Alternative graphing of Supplementary table 4 and Figure 2A. 7 *in vitro* studies investigating the efficacy  
 721 of Delta CCP against Omicron with GMT<sub>50</sub> from each study with minimum and maximum dilution titer  
 722 also shown. The absolute values are graphed in the upper panels for WA-1 on left and omicron on right.  
 723 In the lower panels all numbers divided by the minimum value for each study to normalize for WA-1 on  
 724 left and Omicron on right. The GMT<sub>50</sub> approximates 10 with this computational division. Live virus assays  
 725 are on the left and pseudoviral assays on the right.




726  
 727



728

## 729 Supplementary Figure 5

730 Alternative graphing of Supplementary table 5 and Figure 2B. 22 *in vitro* studies investigating the efficacy  
731 of plasma from uninfected recipients of 2 BNT162b2 doses against Omicron with GMT<sub>50</sub> from each study  
732 with minimum and maximum dilution titer also shown. The absolute values are graphed in the upper  
733 panels for WA-1 on left and omicron on right. In the lower panels all numbers divided by the minimum  
734 value for each study to normalize for WA-1 on left and omicron on right. The GMT<sub>50</sub> approximates 10  
735 with this computational division. Live virus assays are on the left and pseudoviral assays on the right.



736


737

738

739

## 740 Supplementary Figure 6

741 Alternative graphing of Supplementary table 6 and Figure 2B. 9 *in vitro* studies investigating the efficacy  
742 of plasma from uninfected recipients of 2 mRNA-1273 doses against Omicron with GMT<sub>50</sub> from each  
743 study with minimum and maximum dilution titer also shown. The absolute values are graphed in the  
744 upper panels for WA-1 on left and omicron on right. In the lower panels all numbers divided by the  
745 minimum value for each study to normalize for WA-1 on left and omicron on right. The GMT<sub>50</sub>  
746 approximates 10 with this computational division. Live virus assays are on the left and pseudoviral assays  
747 on the right.




748

749

750

## 751 Supplementary Figure 7

752 Alternative graphing of Supplementary table 7 and Figure 2B. 17 *in vitro* studies investigating the efficacy  
753 of plasma from infected and vaccinated (2 BNT162b2 doses) subjects (VaxCCP) against Omicron with  
754 GMT<sub>50</sub> from each study with minimum and maximum dilution titer also shown. The absolute values are  
755 graphed in the upper panels for WA-1 on left and omicron on right. In the lower panels all numbers  
756 divided by the minimum value for each study to normalize for WA-1 on left and Omicron on right. The  
757 GMT<sub>50</sub> approximates 10 with this computational division. Live virus assays are on the left and pseudoviral  
758 assays on the right.




759  
760

## 761 Supplementary Figure 8

762 Alternative graphing of Supplementary table 8 and Figure 2B. 17 *in vitro* studies investigating the efficacy  
763 of plasma from uninfected subjects vaccinated with 3 BNT162b2 doses against Omicron with GMT<sub>50</sub> from  
764 each study with minimum and maximum dilution titer also shown. The absolute values are graphed in the  
765 upper panels for WA-1 on left and omicron on right. In the lower panels all numbers divided by the  
766 minimum value for each study to normalize for WA-1 on left and Omicron on right. The GMT<sub>50</sub>  
767 approximates 10 with this computational division. Live virus assays are on the left and pseudoviral assays  
768 on the right.

769




770

771

## 772 Supplementary Figure 9

773 Alternative graphing of Supplementary table 10 and Figure 5. 7 *in vitro* studies investigating the efficacy  
 774 of plasma from (pre-omicron, BA.1 and BA.4/5 CCP) subjects (VaxCCP) against Omicron BA.1, BA.2 and  
 775 BA.4/5 with GMT<sub>50</sub> from each study with minimum and maximum dilution titer also shown. The absolute  
 776 values are graphed in the upper panels for WA-1 on left and omicron on right. In the lower panels all  
 777 numbers divided by the minimum value for each study to normalize for WA-1 on left and Omicron on  
 778 right. The GMT<sub>50</sub> approximates 10 with this computational division. Live virus assays are on the left and  
 779 pseudoviral assays on the right.











780

781

## 782 Supplementary Figure 10


783 Alternative graphing of Supplement table 11 and Figure 5. 9 *in vitro* studies investigating the efficacy of  
784 plasma from (post-COVID-19-BA.1/full vacc plasma) subjects (VaxCCP) against Omicron BA.1, BA.2 and  
785 BA.4/5 with GMT<sub>50</sub> from each study with minimum and maximum dilution titer also shown. The absolute  
786 values are graphed in the upper panels for WA-1 on left and omicron on right. In the lower panels all  
787 numbers divided by the minimum value for each study to normalize for WA-1 on left and Omicron on  
788 right. The GMT<sub>50</sub> approximates 10 with this computational division. Live virus assays are on the left and  
789 pseudoviral assays on the right.



790

## 791 Supplementary Figure 11

792 Alternative graphing of Supplementary table 12 and Figure 5. 8 *in vitro* studies investigating the efficacy  
 793 of plasma from (3 dose BNT162b2 plasma) subjects (VaxCCP) against Omicron BA.1, BA.2 and BA.4/5 with  
 794 GMT<sub>50</sub> from each study with minimum and maximum dilution titer also shown. The absolute values are  
 795 graphed in the upper panels for WA-1 on left and omicron on right. In the lower panels all numbers  
 796 divided by the minimum value for each study to normalize for WA-1 on left and Omicron on right. The  
 797 GMT<sub>50</sub> approximates 10 with this computational division. Live virus assays are on the left and pseudoviral  
 798 assays on the right.



799